This week in Orthopaedic Oncology

Sep 14–20, 2026 · 6 new studies, 3 reviews · Orthopaedic Oncology archive · All weeks

The new Orthopaedic Oncology research The Reduction sent the week of Sep 14–20, 2026, with the week’s most recent reviews, each with a one-line summary.

Get papers like these by email, free: subscribe to The Reduction, focused on your interests, on the days you pick.

New research

  1. Beyond Anatomical Resectability: A Hypermetabolic and Highly Aggressive Subtype of Spinal Chordoma Associated with Cancer-Specific Progression.

    The Spine Journal · Sep 18 2026 · PubMed

    In 36 spinal chordoma patients, PET/CT-derived metabolic burden plus SINS>10 and Enneking stage IIB identified a hypermetabolic, aggressive subtype with high risk of recurrence, metastasis, or death, enabling a preoperative risk score.

  2. Intraoperative Evaluation of Sarcoma Surgical Margins With Indocyanine Green Fluorescence Imaging: Results From an Observational Study.

    Journal of Surgical Oncology · Sep 17 2026 · PubMed

    In 51 sarcoma resections, ICG fluorescence with an SBR cutoff of 1.67 was highly sensitive for detecting positive margins but not specific enough to replace surgeon judgment, suggesting a combined approach could reduce local recurrence.

  3. Ewing's Sarcoma in Adults: A Predictive Nomogram and Survival Analysis of a Cohort of 937 Patients.

    Journal of Surgical Oncology · Sep 09 2026 · PubMed

    In 937 adults with Ewing sarcoma, a new nomogram incorporating age, stage, site, size, surgery, and chemotherapy predicted disease-specific survival better than stage alone, aiding individualized prognosis.

  4. Allogenic Red Blood Cell Transfusion Increases Risk of Overall Infection After Surgery for Spinal Metastasis: A Retrospective Multi-Institutional Cohort Study of 796 Patients.

    Spine · Sep 07 2026 · PubMed

    In 796 spinal metastasis surgery patients, allogenic RBC transfusion was independently and dose-dependently associated with higher 30-day infection risk with no safe transfusion threshold identified, supporting restrictive transfusion strategies.

  5. Strategies for Pediatric Diaphyseal Bone Reconstruction of the Lower Limb After Oncologic Resection: A Multicenter Retrospective Analysis.

    Journal of Bone Oncology · Aug 17 2026 · PubMed

    In 133 pediatric patients undergoing biological reconstruction after lower-limb diaphyseal tumor resection, union rates (~73%) and complication risks were similar across IMT, vascularized fibula, and combined techniques, with tibial location predicting faster, more reliable healing.

  6. Association between serum preptin levels and bone metastasis in newly diagnosed prostate cancer: a prospective exploratory study.

    Journal of Bone Oncology · Aug 07 2026 · PubMed

    In newly diagnosed prostate cancer, serum preptin levels did not differ between patients with and without bone metastasis, indicating it is not a useful biomarker for metastatic status.

Recent reviews

  1. The Landmark Series: Multimodal Management of Oligometastatic Sarcoma.

    Annals of Surgical Oncology · Nov 2024 · PubMed

    This review discusses multidisciplinary use of metastasis-directed local therapies (SABR, ablation, metastasectomy) for oligometastatic sarcoma, weighing pros/cons of each modality in complex oncologic care.

  2. Orthopaedic Manifestations of Melanoma and Their Management.

    Journal of the American Academy of Orthopaedic Surgeons · Jul 01 2020 · PubMed

    This review outlines the musculoskeletal manifestations of melanoma and stresses that orthopaedic surgeons should maintain suspicion for melanoma when evaluating pigmented lesions or metastatic bone disease.

  3. Tumors of the Hand and the Wrist.

    JBJS Reviews · Jun 2020 · PubMed

    Most hand/wrist tumors are benign (commonly ganglion cysts and enchondromas), but malignancy can mimic benign lesions, so advanced imaging and biopsy should precede definitive treatment when diagnosis is unclear.

← Week of Aug 31 – Sep 6, 2026

Home  ·  All weeks  ·  Archive  ·  Subscribe  ·  FAQ

© 2026 The Reduction